Evidence map›Paper›PMID 39866912›Full record

ArticleJCEM case reports2025

Panhypopituitarism in Neurosarcoidosis: Pituitary-Hypothalamic Involvement Successfully Managed With Rituximab.

Regina de Miguel Ibañez, Pattsy Etual Espinosa Cárdenas, Manuel Ramón García Sáenz, Bayron A Sandoval Bonilla

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Regina de Miguel IbañezEndocrinology Service, Specialty Hospital of the National Medical Center Siglo XXI, Mexican Social Security Institute, Mexico City 06720, Mexico.ORCID https://orcid.org/0000-0003-2502-305X
Pattsy Etual Espinosa CárdenasEndocrinology Service, Specialty Hospital of the National Medical Center Siglo XXI, Mexican Social Security Institute, Mexico City 06720, Mexico.ORCID https://orcid.org/0000-0001-7590-7262
Manuel Ramón García SáenzEndocrinology Service, Specialty Hospital of the National Medical Center Siglo XXI, Mexican Social Security Institute, Mexico City 06720, Mexico.ORCID https://orcid.org/0000-0001-9216-0383
Bayron A Sandoval BonillaNeurosurgery Service, Specialty Hospital of the National Medical Center Siglo XXI, Mexican Social Security Institute, Mexico City 06720, Mexico.ORCID https://orcid.org/0000-0001-6819-3556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurosarcoidosis (NS) is a rare form of sarcoidosis, with isolated hypothalamic-pituitary involvement being exceptionally uncommon. We report a 20-year-old woman presenting with polyuria, galactorrhea, amenorrhea, and substantial weight loss. Hormonal evaluation revealed hypopituitarism with arginine-vasopressin deficiency and hyperprolactinemia. Magnetic resonance imaging demonstrated pituitary stalk thickening and suprasellar extension, initially suggestive of hypophysitis. High-dose glucocorticoid therapy resulted in partial regression of the pituitary lesion but persistence of suprasellar involvement, prompting a transcranial stereotactic biopsy. Histopathological analysis confirmed isolated NS with noncaseating granulomas. The patient was treated with rituximab after partial response to glucocorticoids, achieving significant clinical and radiological improvement, although hormonal axis recovery was not observed. Hormone replacement therapy remains necessary. The case met the criteria for definitive type b NS, as no extraneural involvement was identified. This case underscores the diagnostic challenges of isolated NS and highlights the importance of considering histopathological confirmation in patients without systemic manifestations to guide treatment. Glucocorticoids are first-line therapy, but rituximab may be effective as a second-line option for refractory cases. Early diagnosis and tailored therapy are essential to improving outcomes in this rare and challenging condition.

Indexed as

hypopituitarismnervous system sarcoidosispituitary diseasessarcoidosis

Identifiers

PMID39866912
PMCPMC11758143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.